DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have been given a consensus recommendation of “Moderate Buy” by the fifteen ratings firms that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $139.33.

DXCM has been the topic of several research reports. Canaccord Genuity Group upped their target price on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. Morgan Stanley reduced their price objective on DexCom from $132.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. UBS Group upped their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Raymond James upped their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday, April 26th. Finally, StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $119.24, for a total value of $77,744.48. Following the transaction, the executive vice president now directly owns 67,560 shares in the company, valued at approximately $8,055,854.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $119.24, for a total value of $77,744.48. Following the transaction, the executive vice president now directly owns 67,560 shares in the company, valued at approximately $8,055,854.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bridgette P. Heller sold 1,000 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the transaction, the director now owns 25,349 shares in the company, valued at $2,878,378.95. The disclosure for this sale can be found here. Insiders have sold a total of 4,112 shares of company stock worth $480,861 in the last three months. 0.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On DexCom

Large investors have recently modified their holdings of the stock. Crewe Advisors LLC acquired a new stake in shares of DexCom in the first quarter valued at about $29,000. DSM Capital Partners LLC acquired a new stake in shares of DexCom in the fourth quarter valued at about $28,000. Riverview Trust Co acquired a new stake in shares of DexCom in the first quarter valued at about $32,000. Valley National Advisers Inc. grew its stake in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares in the last quarter. Finally, MV Capital Management Inc. grew its stake in shares of DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after buying an additional 138 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Up 0.9 %

Shares of DXCM stock opened at $111.66 on Wednesday. The business’s fifty day moving average price is $118.01 and its 200 day moving average price is $124.64. DexCom has a 1-year low of $74.75 and a 1-year high of $142.00. The firm has a market capitalization of $44.40 billion, a PE ratio of 72.04, a P/E/G ratio of 2.73 and a beta of 1.16. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. As a group, sell-side analysts forecast that DexCom will post 1.78 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.